IPO
The company has nine drug candidates in human clinical trials.
Consumer healthcare company HRA Pharma grew their total group revenues by 20.8% in 2019 with EBITDA growing by 30%
Numab Therapeutics announced the closing of its Series B financing round at a total volume of CHF 22M. New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella.
Polarean Imaging plc announces that it has issued 232,010 new ordinary shares of £0.00037 each in the capital of the Company at par value, following the exercise of warrants by Amphion Innovations plc.
The company offered 12 million shares at $18 per share and raised $216 million, 72% more than originally expected.
4basebio AG announces the allotment ratio and the final number of shares for the announced share buyback program.
Montis Biosciences launched with €8,4 million seed financing and a novel approach to immune-oncology
Montis Biosciences announces its launch with €8,4 million in seed financing from an international investor syndicate to investigate interactions between perivascular macrophages and tumor vasculature.
“The good performance we saw in the third quarter has continued to further improve.
David Roth, Chief Financial Officer of 4basebio AG, comments: “4basebio can now successfully acquire the desired number of shares in full.
Revolution Medicines snagged $238 million through its initial public offering to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.
PRESS RELEASES